On July 7, 2021 Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, reported that senior members of the executive team will be participating at the following events (Press release, Crescendo Biologics, JUL 7, 2021, View Source [SID1234584666]). They look forward to meeting investors to discuss the Company’s business strategy, technology, discovery platform and development programmes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Blair Biotech Focus Conference 2021, 14-15 July 2021
Participation in Panel II – Moving Beyond Monoclonals: The Potential of Multispecific Therapies on 14 July at 11:20 am EDT, 4:20 pm BST
Solebury Trout & Venrock’s 5th Annual EU Investor Tour, 14 July 2021
Presentation at 11:15 am EDT, 4:15 pm BST
LifeSci Private Company Summer Symposium 2021, 21 July 2021
Fireside chat at 9:25 am EDT, 2:25 pm BST
BTIG Virtual Biotechnology Conference, 10 August 2021
Fireside chat at 11:30 am EDT, 4:30 pm BST
If you would like to meet the team at these events, please contact the Company via email at [email protected].

Please refer to individual conference websites for further information and updated schedules.

On July 7, 2021 SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, reported that Eric Francois, Chief Financial Officer, will present at Ladenburg Thalmann’s virtual Healthcare Conference on July 14th, 2021 (Press release, Scynexis, JUL 7, 2021, View Source [SID1234584665]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Information:

The webcast will be made available for 3 months and can be found on the SCYNEXIS website at: View Source

On July 7, 2021 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, reported that it will participate in the Ladenburg Thalmann’s Virtual 2021 Healthcare Conference held July 13-14, 2021 (Press release, Cyclacel, JUL 7, 2021, View Source [SID1234584664]). Spiro Rombotis, President & Chief Executive Officer, will present an overview of Cyclacel’s business followed by an analyst-led fireside chat.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 7, 2021 Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Wednesday, July 14, 2021 at 1:00 p.m. Eastern Time (Press release, Leap Therapeutics, JUL 7, 2021, View Source [SID1234584663]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and may be accessed on the Investors page of the company’s website at View Source, where a replay of the event will also be available for a limited time.

On July 7, 2021 UroGen Pharma Ltd (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, reported that it will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021 at 12:00pm Eastern Time (Press release, UroGen Pharma, JUL 7, 2021, View Source [SID1234584662]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the website for approximately 30 days.